Claim Missing Document
Check
Articles

Found 3 Documents
Search

Neoadjuvant Lenvatinib in Advanced Unresectable Thyroid Carcinoma: Case Series and Literature Review Albert, Albert; Manginstar, Christian O.; Saleh, Denny; Merung, Marselus A.
e-CliniC Vol. 13 No. 1 (2025): e-CliniC
Publisher : Universitas Sam Ratulangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35790/ecl.v13i1.58793

Abstract

Abstract: Lenvatinib, a tyrosine kinase inhibitor (TKI), has shown potential as a neoadjuvant therapy for inoperable thyroid cancer (TC). In this case series, we present three patients with unresectable thyroid tumors who responded favorably to lenvatinib treatment. A 60-year-old male with papillary thyroid cancer (PTC) experienced a 60% tumor volume reduction after five months of therapy. A 61-year-old male with medullary thyroid cancer (MTC) saw a 99% reduction after four months of lenvatinib and decrease of serum calcitonin and no residual disease six months after surgery. Lastly, a 67-year-old female with anaplastic thyroid cancer (ATC) showed a 70% tumor reduction and significant symptomatic relief. These cases highlight lenvatinib’s efficacy in reducing tumor size and stabilizing disease, improving surgical outcomes in patients initially deemed inoperable due to locally advanced tumors. Lenvatinib’s antitumor effects, driven by its antiangiogenic properties, suggest its potential as a valuable neoadjuvant treatment option in advanced thyroid cancer. Keywords: thyroid carcinoma; lenvatinib; case series
Efficacy and Safety of Drug Elution Bead-Transarterial Chemoembolization in Advanced Soft Tissue Sarcoma Albert, Albert; Manginstar, Christian O.; Saleh, Denny; Merung, Marselus A.
Medical Scope Journal Vol. 7 No. 2 (2025): Medical Scope Journal
Publisher : Universitas Sam Ratulangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35790/msj.v7i2.58794

Abstract

Abstract: Soft-tissue sarcomas (STS) are rare and heterogeneous tumors originating from mesenchymal tissues. While surgical resection remains the primary treatment, not all patients are eligible for surgery, particularly in advanced stages. Drug-eluting bead transarterial chemoemboli zation (DEB-TACE) is a promising therapeutic option for such cases. This retrospective study evaluated the efficacy and safety of DEB-TACE in 30 patients with advanced STS at Prof. Dr. R. D. Kandou Hospital, Manado, from 2020 to 2023. The overall response rate (ORR) was 76.7% (p<0.05), with five patients achieving complete response and 18 showing partial response. The main adverse reactions included post-embolization syndrome (fever, pain, nausea, vomiting) and grade II or higher bone marrow suppression. Despite a morbidity rate of 93.3%, no treatment-related mortality was observed. In conclusion, DEB-TACE is an effective and safe treatment for advanced STS, providing superior short-term efficacy compared to traditional systemic chemotherapy. Keywords: soft tissue sarcoma; drug eluting bead; transarterial chemoembolization
Dual anti-inflammatory and antimicrobial effects of stingless bee propolis on second-degree burns Manginstar, Christian O.; Tallei, Trina E.; Salaki, Christina L.; Niode, Nurdjannah J.; Jaya, Hendra K.
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.2359

Abstract

Propolis, a natural resinous product from stingless bees, is widely recognized for its anti-inflammatory and antimicrobial properties. However, its combined effects in addressing both inflammation and infection in second-degree burns have remained insufficiently explored. The study aimed to investigate the dual role of propolis in modulating inflammation and preventing bacterial infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in a second-degree burn model. Propolis was collected from stingless bees in Gowa, South Sulawesi, Indonesia, and extracted using methanol. Second-degree burns were induced in male Rattus norvegicus, which were then divided into three groups: one treated with propolis, another silver sulfadiazine (positive control), and third with NaCl (negative control). After seven days of treatment, the expression of tumor necrosis factor-alpha (TNF-α) and vascular endothelial growth factor (VEGF) proteins in wound samples was analyzed using immunohistochemistry. The antimicrobial activity of the propolis extract was assessed using the disc diffusion assay, followed by minimum inhibitory concentration (MIC) testing. Network pharmacology analysis was also conducted to assess the anti-inflammatory activity of propolis. Results showed that propolis significantly reduced TNF-α expression and increased VEGF expression, which might enhance VEGF-mediated angiogenesis, leading to improved wound healing compared to controls. The antimicrobial tests demonstrated strong activity against MRSA and P. aeruginosa, with inhibition zones correlating with higher extract concentrations. The MIC value of the propolis extract was 198.66 µg/µL against MRSA and 212.06 µg/µL against P. aeruginosa. Network pharmacology analysis revealed key proteins, including Jun proto-oncogene (JUN), estrogen receptor 1 (ESR1), signal transducer and activator of transcription 3 (STAT3), and proto-oncogene tyrosine-protein kinase Src (SRC), involved in the regulation of TNF-α and VEGF, further supporting the synergistic effects of propolis. This study demonstrates that stingless bee propolis effectively promotes tissue regeneration and prevents infection in second-degree burns, highlighting its potential as an alternative to conventional treatments for wound care.